At long last, No­var­tis’ ra­dio­phar­ma drug Plu­vic­to gets an ex­pand­ed la­bel

No­var­tis’ prostate can­cer ra­dio­phar­ma­ceu­ti­cal Plu­vic­to has net­ted a high­ly an­tic­i­pat­ed and high­ly de­layed ex­pand­ed in­di­ca­tion.

The FDA on Fri­day ap­proved the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER